Source-grounded facts extracted from BIO-RAD LABORATORIES, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BIO-RAD LABORATORIES, INC. reported first quarter ended March 31, 2026 results: revenue $592.1 million, net income $(527.1) million, EPS $(19.55) per diluted share.
“Financial Results Highlights GAAP Results Q1 2026 Q1 2025 Net sales (millions) $ 592.1 $ 585.4 Gross margin 52.3 % 52.3 % Income from operations (millions) $ 34.1 $ 23.7 Net income (loss) (millions) $ (527.1) $ 64.0 Income (loss) per diluted share $ (19.55) $ 2.29”
Norman Schwartz changed role as President at BIO-RAD LABORATORIES, INC..
“Effective on Mr. DiVincenzo’s September 9, 2024 start date as the Company’s President and Chief Operating Officer, Norman Schwartz will continue as the Company’s Chief Executive Officer and Chairman of the Board and will no longer be the Company’s President.”
Andrew Last departed as Executive Vice President, Chief Operating Officer at BIO-RAD LABORATORIES, INC..
“Dr. Last will be retiring from his position on September 5, 2024.”
Jonathan P. DiVincenzo was appointed as President and Chief Operating Officer at BIO-RAD LABORATORIES, INC..
“On August 20, 2024, Bio-Rad Laboratories, Inc. (the “Company”) announced the appointment by the Board of Directors of the Company of Jonathan P. DiVincenzo as the Company’s President and Chief Operating Officer (including as principal operating officer), effective September 9, 2024.”
BIO-RAD LABORATORIES, INC. reported the first quarter ended March 31, 2024 results: revenue $610.8 million, net income $383.9 million, EPS $13.45 per share, on a diluted basis.
“Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2024. First-quarter 2024 total net sales were $610.8 million, a decrease of 9.8 percent compared to $676.8 million reported for the first quarter of 2023. On a currency-neutral basis, quarterly sales decreased 9.6 percent compared to the same period in 2023. Life Science segment net sales for the first quarter were $241.7 million, a decrease of 25.3 percent compared to the same period in 2023. On a currency-neutral basis, Life Science segment sales decreased by 25.2 percent compared to the same quarter in 2023. The currency-neutral year-over-year sales decrease was broad-based and was primarily driven by ongoing weakness in the biotech and biopharma end-markets and the economic environment in China. Clinical Diagnostics segment net sales for the first quarter were $368.6 million, an increase”
BIO-RAD LABORATORIES, INC. shareholders approved Approval of the Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan, as amended at the 2024-04-23 meeting.
“3. The proposal to approve the Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan, as amended was approved and received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows:”
BIO-RAD LABORATORIES, INC. shareholders approved Ratification of KPMG LLP as independent auditors at the 2024-04-23 meeting.
“2. The proposal to ratify the selection of KPMG LLP as the Company’s independent auditors for the fiscal year ending December 31, 2024 was ratified and received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows:”
BIO-RAD LABORATORIES, INC. shareholders approved Election of Directors at the 2024-04-23 meeting.
“1. Each of the nominated directors was elected and received the affirmative vote of a majority of the votes cast in the respective class of Common Stock, as follows:”
Roop K. Lakkaraju was appointed as Executive Vice President and Chief Financial Officer (and principal financial officer) at BIO-RAD LABORATORIES, INC..
“On April 26, 2024, the Company disclosed that Roop K. Lakkaraju, the Company’s Executive Vice President and Chief Financial Officer (and principal financial officer) will act as the Company’s principal accounting officer.”
James J. Barry was appointed as Executive Vice President and President, Life Science Group at BIO-RAD LABORATORIES, INC..
“On April 24, 2024, James J. Barry, currently the Company’s Senior Vice President of Global Manufacturing, was appointed to the position of Executive Vice President and President, Life Science Group, effective May 1, 2024.”
Simon May resigned as Executive Vice President and President, Life Science Group at BIO-RAD LABORATORIES, INC..
“On April 22, 2024, Simon May, the Executive Vice President and President, Life Science Group, of Bio-Rad Laboratories, Inc. (the “Company”) and a named executive officer of the Company, notified the Company of his plans to resign from the Company to pursue another opportunity, effective as of May 1, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.